Weight Loss Drug Semaglutide (Ozempic®) Faces Global Patent Expiry in 2026 — But U.S. and Europe Stay Protected Until 2031
Key Highlights Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity treatment, sold under Ozempic®, Wegovy®, and Rybelsus®.…